Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TIAM1 variants improve clinical outcome in neuroblastoma.

Oncotarget - 11 Jul 2017

Sanmartín Elena, Yáñez Yania, Fornés-Ferrer Victoria, Zugaza José L, Cañete Adela, Castel Victoria, Font de Mora Jaime

Abstract excerpt

Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer. Neuroblastoma is a tumor of the peripheral sympathetic nervous system for which only a few driver alterations have been described including MYCN amplification and ALK mutations. We assessed 106 primary neuroblastoma tumors by next generation sequencing using a customized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cell Line, Tumor
Share to Computational Biology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Genes, myc

Share to High-Throughput Nucleotide Sequencing

Share to Kaplan-Meier Estimate

Share to Neuroblastoma

Source

Open in PubMed Open full text

Identifiers

PMID: 28423360
DOI: 10.18632/oncotarget.16787
PMCID: PMC5542186

Genes

TIAM1
ALK
MYCN
MYC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TIAM1 variants improve clinical outcome in neuroblastoma.PMID 28423360Read ↗

The genetic landscape of high-risk neuroblastoma.Semantic proximity Read ↗

Research progress of neuroblastoma related gene variations.Semantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read ↗

A mechanistic classification of clinical phenotypes in neuroblastomaSemantic proximity Read ↗

Targeting Pathways in Neuroblastoma: Advances in Treatment Strategies and Clinical OutcomesSemantic proximity Read ↗

High Myc pathway activity and low stage of neuronal differentiation associate with poor outcome in neuroblastomaSemantic proximity Read ↗

Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression.Semantic proximity Read ↗

Neuroblastoma and MYCN.Semantic proximity Read ↗

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumorsSemantic proximity Read ↗

Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma.Semantic proximity Read ↗

Somatic structural variation targets neurodevelopmental genes and identifies SHANK2 as a tumor suppressor in neuroblastoma.Semantic proximity Read ↗

Somatic structural variation targets neurodevelopmental genes and identifies <i>SHANK2</i> as a tumor suppressor in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.